Modality
mAb
MOA
EGFRi
Target
PD-L1
Pathway
NF-κB
PompeHCCCrohn's
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Dec 2030
Phase 2Current
NCT03392000
1,439 pts·Pompe
2020-11→2027-10·Not yet recruiting
NCT05603332
214 pts·HCC
2025-11→2030-12·Recruiting
1,653 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-021.5y awayPh2 Data· Pompe
2030-12-114.7y awayPh2 Data· HCC
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Not yet…
P2
Recruit…
Catalysts
Ph2 Data
2027-10-02 · 1.5y away
Pompe
Ph2 Data
2030-12-11 · 4.7y away
HCC
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03392000 | Phase 2 | Pompe | Not yet recr... | 1439 | PANSS |
| NCT05603332 | Phase 2 | HCC | Recruiting | 214 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Bemaderotide | Revolution Medicines | Phase 3 | BCL-2 |